News headlines about Retrophin (NASDAQ:RTRX) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Retrophin earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.648831613198 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of research firms recently weighed in on RTRX. ValuEngine lowered shares of Retrophin from a “hold” rating to a “sell” rating in a report on Friday, July 28th. BidaskClub raised shares of Retrophin from a “hold” rating to a “buy” rating in a report on Wednesday, August 16th. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Retrophin currently has an average rating of “Buy” and a consensus target price of $32.33.

Retrophin (NASDAQ RTRX) opened at 24.08 on Monday. The stock has a 50 day moving average of $22.83 and a 200-day moving average of $19.67. The company’s market cap is $924.31 million. Retrophin has a one year low of $15.55 and a one year high of $25.11.

Retrophin (NASDAQ:RTRX) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The firm had revenue of $38.80 million for the quarter, compared to analysts’ expectations of $37.36 million. During the same period in the prior year, the firm earned $0.07 EPS. Retrophin’s revenue for the quarter was up 16.5% compared to the same quarter last year. On average, equities analysts predict that Retrophin will post ($1.13) EPS for the current fiscal year.

In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of Retrophin stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total transaction of $31,005.00. Following the transaction, the chief operating officer now owns 13,622 shares of the company’s stock, valued at $306,495. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.41% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Retrophin (RTRX) Receiving Somewhat Favorable News Coverage, Study Finds” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Stock Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related stocks with our FREE daily email newsletter.